Ramipril did not reduce incident diabetes in patients with impaired glycemic control

Gandhi, Gunjan Y.; Isley, William L.
January 2007
ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p10
Academic Journal
The article discusses a research study regarding the effectiveness of ramipril in reducing the risk for diabetes in patients with impaired glycemic control. The study was conducted by researcher J. Bosch and colleagues. Ramipril did not reduce diabetes in patients with impaired glucose tolerance. The meta-analysis of randomized placebo-controlled trials of angiotensin-converting enzyme inhibitors, showed reduction in diabetes in patients with hypertension and cardiovascular disease.


Related Articles

  • Ramipril: A Review of its Use in Preventing Cardiovascular Outcomes in High-Risk Patients. Anderson, Vanessa R.; Perry, Caroline M.; Robinson, Dean M. // American Journal of Cardiovascular Drugs;2006, Vol. 6 Issue 6, p417 

    Ramipril is an oral, non-sulfhydryl ACE inhibitor thought to act in the renin-angiotensin-aldosterone system to decrease vasopressor activity, aldosterone secretion, and bradykinin degradation.Ramipril is generally well tolerated and effective in the treatment of patients aged ≥55 years at...

  • 'Untitled' Fitchett, David // CMAJ: Canadian Medical Association Journal;6/24/2003, Vol. 168 Issue 13, p1646 

    Relates the therapeutic benefits of ramipril. Overview of the Heart Outcomes Prevention Evaluation (HOPE) study which showed the reduction of cardiovascular mortality; Study which revealed the efficacy of the drug; Factor attributed to the sales increase of the drug after publication of the...

  • Nephroprotection by long--term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats. Linz, Wolfgang; Becker, Reinhard H.A.; Scholkens, Bernward A.; Wiemer, Gabriele; Keil, Manfred; Langer, Karl Heinz // Kidney International;Dec1998, Vol. 54 Issue 6, p2037 

    Focuses on a study on the effect of angiotensin-converting enzyme (ACE) inhibitor ramipril treatment in rats developing malignant hypertension. Methods; Significance of ramipril on body weights; Efficacy of ramipril.

  • Review: ACE inhibitors and angiotensin-receptor blockers reduce diabetes in hypertension and other CV risk factors.  // ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p11 

    The article discusses a research study regarding the effectiveness of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II type 1 receptor blockers in reducing new-onset diabetes mellitus. The study was conducted by researcher K.L. McCall and colleagues, and was published in the...

  • Ramipril-Associated Hepatotoxicity. Yeung, Elaine; Wong, Florence S.; Wanless, Ian R.; Shiota, Koji; Guindi, Maha; Joshi, Supriya; Gardiner, Geoffrey // Archives of Pathology & Laboratory Medicine;Nov2003, Vol. 127 Issue 11, p1493 

    Context.--Angiotensin-converting enzyme inhibitors are prescribed for many cardiovascular and renal diseases. Adverse hepatic events, especially cholestasis, have rarely been reported with captopril, enalapril, lisinopril, and fosinopril. To date, hepatic injury associated with ramipril has not...

  • Spotlight on Ramipril in the Prevention of Cardiovascular Outcomes. Gregory T. Warner; Caroline M. Perry // American Journal of Cardiovascular Drugs;Mar2003, Vol. 3 Issue 2, p113 

    Ramipril (Altace®), an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which is rapidly hydrolyzed after absorption to the active metabolite ramiprilat. Earlier trials have shown that ACE inhibitors, when given to patients with low ejection fractions, have reduced the relative...

  • Ramipril use in Canada: HOPE or HYPE? Pilote, Louise // CMAJ: Canadian Medical Association Journal;3/4/2003, Vol. 168 Issue 5, p568 

    Examines the use of angiotensin-convertin-enzyme (ACE) inhibitors for treatment of cardiovascular and renal conditions. Role that ACE inhibitors play in altering the balance between the vasoconstrictive, salt-retentive and hypertrophic properties of angiotensin II, and in interfering with the...

  • The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. Tu, Karen; Mamdani, Muhammad M.; Jacka, Robert M.; Forde, Natalie J.; Rothwell, Deanna M.; Tu, Jack V. // CMAJ: Canadian Medical Association Journal;3/4/2003, Vol. 168 Issue 5, p553 

    Background: The Heart Outcomes Prevention Evaluation (HOPE), a Canadian-led, multicentre, randomized controlled trial, demonstrated the effectiveness of the ACE inhibitor ramipril in the secondary prevention of cardiovascular disease in patients who were at high risk for cardiovascular events...

  • In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events. Dans, Antonio L.; Koon Teo; Gao, Peggy; Jyh-Hong Chen; Kim Jae-Hyung; Yusoff, Khalid; Chaitraphan, Suphachai; Zhu, Jun; Liu Lisheng; Yusuf, Salim // PLoS Clinical Trials;Dec2010, Vol. 7 Issue 12, Special section p1 

    Background and Objectives: Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/ day) in reducing cardiovascular events. Clinicians in Asia...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics